Understanding the Market | GRANDPHARMA rose over 6% in the morning as the new myopia drug GPN00884 recently started its Phase IIa clinical trial in China
GRANDPHARMA rose over 6% in the morning, and as of the time of writing, it has increased by 6.42%, trading at HKD 8.79, with a transaction volume of HKD 101 million. In terms of news, GRANDPHARMA recently announced that the global innovative ophthalmic drug GPN00884, used to delay the progression of myopia in children, has completed the enrollment and dosing of the first patient in its Phase IIa clinical study in China. This means that GPN00884 will enter an important phase to explore drug dosage and assess preliminary efficacy. If the expected drug effectiveness is successfully realized, clinical practice may welcome a new solution for alleviating the progression of myopia in children. It is worth noting that in July of this year, the oxymetazoline hydrochloride nasal spray (OC-01) was launched in mainland China, revolutionizing the treatment experience for dry eye patients through nasal spray. Recently, GRANDPHARMA successfully held a national launch conference for OC-01, taking advantage of the 11th Global Dry Eye Academic Conference themed "Caring for Dry Eye Patients, Welcoming the Era of Native Tears - 2025 New Advances in Dry Eye Diagnosis and Treatment and the Construction of Ocular Surface Health Ecology," officially announcing the arrival of a new era in dry eye treatment from "external replacement" to "internal awakening."
According to Zhitong Finance APP, GRANDPHARMA (00512) rose over 6% in the morning, and as of the time of publication, it increased by 6.42%, reaching HKD 8.79, with a transaction volume of HKD 101 million.
In terms of news, GRANDPHARMA recently announced that the global innovative ophthalmic drug GPN00884, used to delay the progression of myopia in children, has completed the enrollment and administration of the first patient in the Phase IIa clinical study conducted in China. This means that GPN00884 will enter an important stage of exploring drug dosage and assessing preliminary efficacy. If the expected drug effectiveness is successfully realized, a new solution for alleviating the progression of myopia in children may emerge in clinical practice.
It is worth noting that in July of this year, the oxymetazoline hydrochloride nasal spray (OC-01) was launched in mainland China, revolutionizing the treatment experience for dry eye patients through nasal spray. Recently, GRANDPHARMA successfully held a national launch conference for OC-01, taking advantage of the 11th Global Dry Eye Academic Conference themed "Caring for Dry Eye Patients, Welcoming the Era of Native Tears - New Advances in Dry Eye Diagnosis and Treatment and the Construction of Ocular Surface Health Ecology 2025," officially announcing the arrival of a new era in dry eye treatment from "external replacement" to "internal awakening."
